To SMILE or not: Supportive care matters

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 1015-1016

  Chan, Alexandre ^a   Tang, Tiffany ^b   Ng, Terence ^b   Shih, Vivianne ^b   Tay, Kevin ^b   Tao, Miriam ^b   Quek, Richard ^b   Lim, Soon Thye ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BORTEZOMIB; COTRIMOXAZOLE; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; PENTAMIDINE; ANTINEOPLASTIC AGENT;

AEROSOL; ANTIBIOTIC PROPHYLAXIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DRUG ACTIVATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ERWINIA; ESCHERICHIA COLI; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION; INFECTION PREVENTION; LETTER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS JIROVECI; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SEPTIC SHOCK; TREATMENT OUTCOME; FEMALE; MALE; NOSE TUMOR; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; NOSE NEOPLASMS;

EID: 84860637699     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.7098     Document Type: Letter

References (11)

1. Yamaguchi M, Kwong Y-L, Kim WS, et al: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin Oncol 29:4410-4416, 2011
2. National Comprehensive Cancer Network: Prevention and treatment of cancer-related infections. http://www.nccn.org/network/business-insights/flash- updates/flash-update-information.asp?FlashID=14
3. Chan A, Tan SH, Wong CM, et al: Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: A Delphi survey of oncology pharmacists. Clin Ther 31:2379-2386, 2009
4. Stock W, Douer D, DeAngelo DJ, et al: Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel. Leuk Lymphoma 52:2237-2253, 2011
5. Pieters R, Hunger SP, Boos J, et al: L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 117:238-249, 2011
6. Yong W, Zheng W, Zhu J, et al: L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 88:647-652, 2009
7. Obama K, Tara M, Niina K: L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 78:248-250, 2003 (Pubitemid 37288512)
8. Yamaguchi M, Suzuki R, Kwong YL, et al: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016-1020, 2008 (Pubitemid 351997606)
9. Huang Y, de Reyniè s A, de Leval L, et al: Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115:1226-1237, 2010
10. Ng SB, Selvarajan V, Huang G, et al: Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 223:496-510, 2011
11. Farid M, Yau YW, Tay K, et al: A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma. Acta Oncol 50:589-590, 2011